Current treatments for AD, such as cholinesterase inhibitors, NMDA receptor antagonists (Liu et al., 2019), and therapies targeting Aβ and tau proteins (Congdon and Sigurdsson, 2018), primarily alleviate symptoms by modulating neurotransmitter levels. This evidence concerns the gene MAPT and Alzheimer disease.